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Abstract
Purpose: To quantify incidental thyroid pathology including malignancy on routine
18F-FDG PET-CT scans
To compare standardised uptake values (SUVmax) in thyroid malignancy subtypes
Methods and materials: This is a retrospective study of all 18F-FDG PET-CT scans
(n = 6179) performed in a teaching hospital between June 2010 and May 2019.
RIS database search of reports for the word “thyroid” was performed. Studies with
evidence of thyroid uptake were included. Patient age and gender, primary indication
for PET scan (malignant or non-malignant), thyroid result on PET (diffuse or focal tracer
uptake, SUVmax), ultrasound and FNAC results were recorded.
Results: Incidental abnormal thyroid tracer uptake as a proportion of all 18F-FDG PET-
CT scans was 4.37% (n = 270). Out of region patients (n = 87) whose records could not
be obtained were excluded leaving a study group of n = 183. Ninety-four in this group
had focal uptake, and 89 had diffuse uptake. Fifty-five patients in the focal group had
undergone further investigations. Of these, 30 were thought to be benign on USS
alone, and 25 patients underwent USS/FNAC. Thirteen (24%) malignancies were
identified (5 papillary, 6 follicular, 1 poorly differentiated thyroid cancer, 1 metastatic
malignancy). Mean SUVmax for papillary carcinoma was noted to be 8.2 g/ml, and
follicular carcinoma was 12.6 g/ml.
Conclusion: Incidental abnormal thyroid 18F-FDG PET-CT uptake in PET-CT scans of
4.37% is in keeping with the known limited literature. Rather similar number of patients
was noted in the focal and diffuse tracer uptake categories in the final study group.
Around quarter of the focal lesions were identified to be malignant, implying focal
lesions should always be further investigated.
Keywords: Thyroid malignancy, Hybrid imaging, Positron emission tomography
computed tomography, 18-Fluorodeoxyglucose, Standardised uptake value
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Introduction
The increasing role of PET-CT in oncological and non-oncological conditions has re-
sulted in an increased detection of PET-CT incidentalomas, commonly involving the
thyroid gland (The Royal College of radiologists, 2012; Delivanis & Castro, 2018; Vassi-
liadi & Tsagarakis, 2011).
The tracer 18F-FDG1 used in PET-CT can incidentally accumulate in the thyroid
gland, either diffusely or focally. Incidental focal 18F-FDG uptake within the thyroid
gland has previously been found to occur in 1.2–4.3% of all PET-CT scans in patients
scanned for an alternative indication (Kao et al., 2012; Soelberg et al., 2012; Cohen
et al., 2001; Kang et al., 2003; Chen et al., 2005; Chen et al., 2009; Ho et al., 2011). Pa-
tients with focal uptake within the thyroid gland are at a higher risk of malignancy,
with studies reporting between 26 and 50% (Kao et al., 2012; Soelberg et al., 2012; Co-
hen et al., 2001; Chen et al., 2005; Chen et al., 2009; Kim et al., 2005; Chu et al., 2006;
Bae et al., 2009). Figures 1 and 2 are two patients in our institution scanned for an al-
ternative indication who subsequently were found to have thyroid malignancy. Further
investigation of focal 18F-FDG uptake with ultrasound and FNAC2 is recommended be-
cause of this increased risk of malignancy (Pencharz et al., 2018; Haugen et al., 2015;
Hoang et al., 2015).
PET-CT can deduce semi-quantitative evaluations of glucose metabolism in tissues
by measuring standardised uptake value (SUVmax) (Chu et al., 2014). The role of SUV-
max in thyroid malignancy is debated as studies have produced conflicting results, and,
although reasonable to suggest that malignancy is associated with a higher SUVmax
value (Kumar et al., 2013), some studies have shown no correlation (Eloy et al., 2009;
Are et al., 2007).
Although the usefulness of SUVmax in thyroid malignancy is questioned, a cytological
diagnosis of focal thyroid FDG-PET incidentalomas is necessary considering the in-
creased risk of malignancy.
The primary aim of our study was to quantify incidental thyroid malignancy on 18F-
FDG PET-CT in patients scanned for an alternative indication. A secondary outcome
was to compare mean, median, and range of SUVmax according to thyroid malignancy
subtypes.
Methods and materials
This is a retrospective study of all 18F-FDG PET-CT scans performed in a large teach-
ing hospital between June 2010 and May 2019. We performed a CRIS (CDN Radiology
Information System) database search, and results were filtered to include the word
“thyroid” within the scan reports. All 18F-FDG PET-CT scans in our institution are
double reported by four experienced consultants, two of whom are also experienced in
routine thyroid imaging. Studies with no thyroid uptake were excluded. We manually
collected patient’s data including age and gender, primary indication for PET-CT scan
(malignant or non-malignant), thyroid result on PET (diffuse or focal uptake of 18F-
FDG), ultrasound result and result of FNAC. Total number of FNAC diagnosed as
118F-fluorodeoxyglucose
2Fine needle aspiration with cytology
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thyroid malignancy and mean SUVmax values of thyroid malignancy subtypes were col-
lected. Those patients who had tracer uptake but were lost to follow-up were excluded.
Results
Six thousand, one-hundred and seventy-nine (n = 6179) 18F-FDG PET scans were performed
during study period. Three-hundred and forty-two (n = 342) results contained the word “thy-
roid” of which two-hundred and seventy (n = 270) scans had increased uptake in thyroid
gland. Eighty-seven (n = 87) patients were excluded (out of region patients, deaths, lost to
follow-up). This left a study group of one-hundred and eighty-three (n = 183) of which one
hundred and twenty-seven (n = 127) were females, and fifty-six (n = 56) were males. Ninety-
four (n = 94) PET-CT scans had focal uptake, and eighty-nine (n = 89) had diffuse uptake. In
our study group, those with diffuse uptake included seventy female patients (n = 70) and nine-
teen (n = 19) male patients. Fifty-seven females (n = 57) and thirty-seven male patients (n =
37) had focal uptake in our study group. Fifty patients in the focal group underwent further in-
vestigations. Of these, 30 were thought to be benign on USS alone and 25 patients underwent
USS/FNAC, where 52% (52%, n = 13/25) were confirmed to be malignancy. Thyroid malig-
nancy subtypes included papillary (n = 5), follicular (n = 6), metastatic malignancy (n = 1) and
poorly differentiated carcinoma of the thyroid (n = 1). Patients who had a previous history of
Fig. 1 Fifty-three-year-old female with a diagnosis of Hodgkin’s lymphoma underwent PET-CT scan to
monitor her response to chemotherapy. PET coronal (a) and axial (b) images show focus of increased tracer
uptake in the left lobe of the thyroid. Image c shows fused axial PET-CT image showing the same
abnormality (SUV max 11.1g/ml). FNAC biopsy showed this to be papillary thyroid carcinoma
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thyroid cancer with increased uptake were included in the study (n = 1). Eight (8/25) path-
ology result confirmed benign lesions including non-neoplastic (n = 2), follicular with Hurthle
cell type changes (n = 1), and colloid nodule (n = 5). The remainder of the FNA biopsies were
deemed indeterminate (n = 4/25) by the reporting pathologist giving a malignancy positive
rate of 62% (13/21) within the confirmed results. Overall, 13 malignancies were identified out
of the 55 patients with focal uptake who underwent further assessment (24%).
Abnormal tracer uptake in the thyroid gland incidentally as a proportion of all 18F-
FDG PET-CT scans was 4.37%. Abnormal focal tracer uptake as a proportion of all
18F-FDG PET-CT scans was 2.77%. Mean SUVmax in focal malignant lesions ranged
from 4 to 35.36 g/ml (Table 1) and in focal benign lesions ranged from 1.6 to 18.2 g/ml
(Table 2). Mean SUVmax value for papillary carcinoma was 8.2 g/ml, and follicular car-
cinoma was 12.6 g/ml. Median SUVmax for papillary carcinoma was 7.4 g/ml, and fol-
licular carcinoma was 8.2 g/ml. Given the small sample size and significant overlap in
the obtained SUVmax data for the two groups, a threshold with a clinically valuable
power cannot be obtained to differentiate benign and malignant tracer uptake and
hence is not stated here.
Fig. 2 Seventy-nine-year-old female with a past medical history of systemic sclerosis and Raynaud’s disease. She
presented with symptoms of weight loss, retrosternal chest discomfort and general cognitive decline. Prior
investigations had shown a raised CRP and normal WCC in her routine blood, and an OGD showed oesophagitis
only. She had a CT CAP and PET-CT to investigate for possibility of an organ tumour/large vessel vasculitis. Image a
shows axial CT with a large left-sided thyroid mass. Image b is a fused axial PET-CT scan showing 33mm × 36mm
metabolically active lesion (SUV max 10.3 g/ml) which occupies much of the left lobe of the thyroid gland and is
responsible for tracheal deviation to the right. FNAC confirmed follicular carcinoma
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Discussion
Incidental abnormal thyroid 18F-FDG uptake as a proportion of all PET-CT scans and inci-
dence of malignancy in focal abnormal thyroid 18F-FDG uptake in our patient group are
both comparable with the available limited literature (Vassiliadi & Tsagarakis, 2011; Kao
et al., 2012; Soelberg et al., 2012; Cohen et al., 2001; Kang et al., 2003; Chen et al., 2005;
Chen et al., 2009; Yi et al., 2005; Ho et al., 2011; Kim et al., 2005; Chu et al., 2006), reiterat-
ing the importance of detecting and investigating focal thyroid uptake on 18F-FDG PET-CT.
Around a quarter of focal thyroid uptake were malignant; hence, focal lesions should be in-
vestigated further, if clinically appropriate. A significant proportion of 18F-FDG PET-CT
scans are performed for known/unknown malignancy, and further assessment of incidental
thyroid lesions may not be possible for many reasons. Regardless, it is important to detect
thyroid lesions in all patients in order to optimise appropriate clinical decision-making.
Some of the patients who underwent USS were deemed benign sonographically despite hav-
ing focal thyroid tracer uptake. It is recommended that all thyroid tracer focal uptake, if clinic-
ally appropriate, are investigated further with an ultrasound and FNAC because of the
increased risk of malignancy (Bae et al., 2009; Pencharz et al., 2018; Haugen et al., 2015). Cur-
rently, we do not have agreed local guidelines for investigation of focal thyroid uptake on 18F-
FDG PET-CT, but based on current recommendations and findings in this study, it would be
our future practice to investigate all focal lesions to undergo FNAC where clinically necessary.
Table 1 The SUVmax values for the FNAC-proven malignancies
Type of malignancy SUV value (g/ml)
Papillary 11.1
Papillary 4
Papillary 5.4
Papillary 13.3
Papillary 7.4
Follicular 10.3
Follicular 7.7
Follicular 35.36
Follicular 6.7
Follicular 6.8
Follicular 8.7
Metastatic malignancy 4.8
Poorly differentiated carcinoma of thyroid 8.9
Table 2 The SUVmax values for the eight FNAC reported benign by the pathologist
Pathological report SUVmax value (g/ml)
Non-neoplastic 18.2
Non-neoplastic 12.48
Follicular adenoma with Hurthle cell type 5.73
Colloid 7.45
Colloid 6.1
Colloid 1.6
Colloid 3.8
Colloid 5.8
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Similar number of diffuse and focal thyroid tracer uptake were found in our study,
and this is important to differentiate them as they have different outcomes for patients.
Abnormal thyroid tracer uptake, diffuse or focal, also appears to be more in females,
and this is comparable with current literature (Stangierski et al., 2014).
Our secondary aim was to compare SUVmax across thyroid malignancy histological
subtypes. Follicular carcinoma has a higher mean, median and range of SUVmax than
papillary carcinoma in this study. Soelberg et al. in their meta-analysis found mean
SUVmax to be 6.9 g/ml in malignant lesions (Soelberg et al., 2012), lower than our find-
ings for both follicular and papillary carcinoma but comparable with our median SUV-
max. Our sample size for each malignancy subtype is low, and mean SUVmax and
median SUVmax might be affected by this, so should be interpreted cautiously.
Our study found malignancies with a wide range of SUVmax values, implying a higher mean
SUVmax does not necessitate malignancy. It is debatable if SUVmax can differentiate between
benign and malignant lesions, but overall it is thought that mean SUVmax is lower in benign
lesions compared to malignant lesions (Soelberg et al., 2012). It is also unclear if a specific
SUVmax indicates malignancy and certain cutoffs have been stipulated. In our study, we were
unable to confidently identify a cutoff point for SUVmax to identify malignancy due to consid-
erable overlap in SUVmax values in both benign and malignant focal uptake lesions. This is
echoed by the results of two smaller studies, which also showed a large overlap in SUVmax
value between benign and malignant lesions (Brindle et al., 2014; Agrawal et al., 2015). With
the findings in this study and other studies, it is difficult to confidently use mean SUVmax value
alone in differentiating between benign and malignant thyroid lesions. There is a role for SUV-
max in thyroid malignancy, but a specific defined value or range cannot be accurately estab-
lished in differentiating between benign or malignant lesions.
There are a few limitations to our study that we acknowledge. Our biggest limitation was
that we excluded nearly a third of patients with focal thyroid tracer uptake who were lost to
our follow-up. Most of those patients were referred to us initially from regional centres, and
their follow-up records or results were not available for our reference. Despite this, the study
still showed the prevalence of incidental thyroid uptake on 18F-FDG PET-CT. Another limita-
tion of our study is that only a word search for “thyroid” was done in our reports, and images
were not reviewed. As described earlier, all our scans are double reported within a pool of 4
experienced consultants, two of whom specialise in thyroid imaging. Most of these patients
undergo scans for known malignancy, and a significant proportion of these scans are reviewed
again for MDT requirements. Furthermore, there is a dedicated discrepancy meeting to iden-
tify reporting errors. We strongly believe, given the above, that the possibility of missing
unreported thyroid lesions in these scans to be very low.
Conclusion
Standardised approach needed for investigation of incidental 18F-FDG PET-CT focal
uptake in the thyroid gland due to high prevalence of malignancy and a combination of
ultrasound with FNAC is advised.
There is conflicting evidence at how to utilise SUVmax in focal thyroid tracer uptake, but its
use in combination with ultrasound and histopathological findings should be sought with fur-
ther bigger studies. We established that SUVmax is relatively higher in follicular carcinoma
than papillary carcinoma; however, further research in large patient groups is needed.
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